Aeterna Zentaris (NASDAQ:AEZS) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.
This table compares Aeterna Zentaris and Trillium Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Aeterna Zentaris has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.
This is a summary of current recommendations for Aeterna Zentaris and Trillium Therapeutics, as reported by MarketBeat.
||Strong Buy Ratings
Trillium Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 100.55%. Given Trillium Therapeutics’ higher probable upside, analysts clearly believe Trillium Therapeutics is more favorable than Aeterna Zentaris.
Earnings and Valuation
This table compares Aeterna Zentaris and Trillium Therapeutics’ revenue, earnings per share and valuation.
||Earnings Per Share
Aeterna Zentaris has higher revenue and earnings than Trillium Therapeutics.
Institutional and Insider Ownership
2.4% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Trillium Therapeutics beats Aeterna Zentaris on 8 of the 11 factors compared between the two stocks.
About Aeterna Zentaris
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
About Trillium Therapeutics
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.